Turnstone Biologics closed US $80M Series D from PFM Health Sciences, Point72, Eventide Asset Management, Surveyor Capital, Ridgeback Capital Investments, Takeda Ventures Inc., CaaS Capital, JM Family Enterprises, Northleaf, 404 Bio, Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.Continue Reading